Back to search

Ireland· IE-PA-PA0822/196/002

Salazopyrin® 500 mg Tablets

A sulfasalazine product containing sulfasalazine, registered in Ireland by Pfizer Healthcare Ireland Unlimited Company. The same ATC class is registered in 17 of our 19 countries.

ATC A07EC01

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedSalazopyrin® 500 mg TabletsATCA07EC01REGISTER NO.IE-PA-PA0822/196/002PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Sulfasalazine is registered in 17 of 19 countries.

Countries holding a registration under ATC A07EC01 (sulfasalazine), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 10 of them publish a price we can compare per daily dose

Sulfasalazine · ATC A07EC01

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of sulfasalazine costs, country by country.

Normalised to the WHO defined daily dose (2 g), the median price runs from $0.43 in France to $1.35 in Switzerland — a ×3.1 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Sulfasalazine · price per daily dose (2 g)

USD · FX 28 Sept 2026

  • CH Switzerland$1.35
  • IT Italy$0.68
  • FR France$0.43
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
Sulfasalazine
Manufacturer
Pfizer Healthcare Ireland Unlimited Company
Country
Ireland (IE)
ATC code
A07EC01
ATC class
Sulfasalazine
Defined daily dose
2 g, O
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    PA0822/196/002

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

466 interactions on record for sulfasalazine.

Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Sulfasalazine · interactions on record

466 records

  • 31 severe
  • 183 moderate
  • 7 minor
  • 243 info

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • MipomersenC10AX11severe
  • LomitapideC10AX12severe

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Sulfasalazine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All sulfasalazine products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Salazopyrin
  • Belgium · Salazopyrine Ec
  • Bulgaria · Сулфасалазин Ен
  • Cyprus · Salazidin Gr
  • Czechia · Salazopyrin En, Sulfasalazin K-En
  • Germany · Azulfidine, Azulfidine Ra
  • Denmark · Salazopyrin, Salazopyrin Entabs
  • Estonia · Salazopyrin En
  • Spain · Salazopyrina
  • Finland · Salazopyrin, Salazopyrin En
  • France · Salazopyrine
  • United Kingdom (Northern Ireland) · Salazopyrin, Salazopyrin En-Tabs
  • Greece · Salopyrine
  • Croatia · Salazopyrin En, Sulfasalazin En Krka
  • Hungary · Salazopyrin En
  • Iceland · Salazopyrin, Salazopyrin En-Tabs
  • Italy · Salazopyrin En
  • Lithuania · Sulfasalazine Krka
  • Luxembourg · Salazopyrine Ec
  • Latvia · Sulfasalazine Krka
  • Malta · Salazidin, Sulfasalazin Heyl
  • Netherlands · Salazopyrine E.C., Salazopyrine Zetpil
  • Norway · Salazopyrin En
  • Poland · Salazopyrin En, Sulfasalazin En Krka
  • Portugal · Salazopirina En
  • Romania · Salazidin, Sulfasalazină En
  • Sweden · Salazopyrin, Salazopyrin En
  • Slovenia · Sulfasalazin Krka
  • Slovakia · Sulfasalazin-En

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4b6a3fc1-0c38-4069-af63-aea4da55f3bc
GET /v1/drugs/4b6a3fc1-0c38-4069-af63-aea4da55f3bc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "A07EC",
    "A07EC01"
  ],
  "strength": null,
  "pa_number": "PA0822/196/002",
  "substances": [
    "Sulfasalazine"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Marketed",
  "authorised_at": "01/04/1977",
  "dispensing_status": "Product subject to prescription which may be renewed (B)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about sulfasalazine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.